The advantage of this tool for high-throughput screening is several-fold: (1) the HMC3 microglia cell line is easy and affordable to grow and maintain, (2) treatment with the combination of Chol + AbO + fructose + LPS appears to adequately reproduce critical aspects of the DAM phenotype observed in AD, and (3) the readouts (total cellular Chol, ATP, and ROS content, ApoE content in the supernatant, phagocytic activity and cell morphology) are also easy and affordable to measure. Here, APOE is linked to Alzheimer disease.